Sanne I, Smego R A, Mendelow B V
Department of Infectious Diseases and Clinical Microbiology, University of Witwaterswand, Johannesburg, Republic of South Africa.
Int J Infect Dis. 2001;5(1):43-8. doi: 10.1016/s1201-9712(01)90048-7.
Effective antiretroviral therapy remains beyond the reach of most human immunodeficiency virus (HIV)-infected persons living in the third world because of its tremendous cost. The cancer drug, hydroxyurea, inhibits HIV-1 replication in vitro and, when combined with didanosine (ddI), results in significant antiretroviral synergy. In vivo, hydroxyurea specifically targets quiescent lymphocytes and macrophages, important cellular reservoirs for HIV-1, and the combination of ddI plus hydroxyurea effectively reduces plasma HIV-1 RNA levels. Combination ddI-hydroxyurea costs about one-eighth as much as currently recommended triple drug combinations, and several countries in Africa are exploring the feasibility of widescale use of ddI-hydroxyurea for their HIV-infected populations. Intrigued by its potential relevance for Africa, the authors reviewed the literature on the in vitro and clinical efficacy of ddI plus hydroxyurea against HIV. The combination of ddI plus hydroxyurea is an effective and potentially more affordable regimen for HIV-infected persons living in poorer countries.
由于成本高昂，大多数生活在第三世界的人类免疫缺陷病毒（HIV）感染者仍无法获得有效的抗逆转录病毒疗法。抗癌药物羟基脲在体外可抑制HIV-1复制，与去羟肌苷（ddI）联合使用时，会产生显著的抗逆转录病毒协同作用。在体内，羟基脲特异性靶向静止淋巴细胞和巨噬细胞，这是HIV-1重要的细胞储存库，ddI加羟基脲的组合可有效降低血浆HIV-1 RNA水平。ddI-羟基脲组合的成本约为目前推荐的三联药物组合的八分之一，非洲的几个国家正在探索对其HIV感染人群广泛使用ddI-羟基脲的可行性。鉴于其对非洲的潜在相关性，作者回顾了关于ddI加羟基脲抗HIV的体外和临床疗效的文献。对于生活在较贫穷国家的HIV感染者来说，ddI加羟基脲的组合是一种有效且可能更经济实惠的治疗方案。
